TrialSignal transduction and targeted therapy2024

The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.

Bo Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.